JAKKS Pacific Partners with Hershey to Launch New Doll Collection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Should l Buy CVS?
JAKKS Pacific (JAKK) announced a new partnership that will bring the Hershey (HSY) branding to JAKKS Pacific's Charming line of small dolls and collectibles. The collection will consist of eight SKUs featuring dolls inspired by treats including Hershey's Kisses, Jolly Rancher, Reese's, Bubble Yum, Twizzlers, and Hershey's Syrup each comes with themed charms and accessories. The first products to launch under the collaboration, The Hershey's Kisses collectibles, will debut exclusively at CVS (CVS) beginning December 26, 2025. The partnership runs through December 31, 2026, with an option for extension.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 77.750
Low
91.00
Averages
96.71
High
105.00
Current: 77.750
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Health Launches $5 Million Pharmacy Scholarship Program
- Scholarship Program Launch: CVS Health has announced a new $5 million scholarship program aimed at supporting aspiring pharmacists in Louisiana, facilitating their pursuit of a Doctor of Pharmacy degree at Xavier University and the University of Louisiana at Monroe, thereby reducing financial barriers and enhancing access to care.
- Commitment to Health Equity: This initiative is part of CVS Health's broader commitment to advancing health equity and expanding access to care by investing in the next generation of healthcare professionals, particularly those from diverse backgrounds who wish to serve in areas with critical healthcare needs.
- Community Impact: Louisiana Governor Jeff Landry emphasized that investing in young people is crucial for the state's future, and CVS Health's initiative will strengthen the local healthcare workforce while promoting overall community health by providing opportunities for education and career development.
- Educational Partnerships: Xavier University and the University of Louisiana at Monroe were selected for their shared commitment to academic excellence and community impact, and CVS Health's scholarship program will create clear pathways for talented individuals to remain in the state and contribute to local healthcare services.
See More
Market Rotation and Healthcare Sector Outlook
- Market Milestones: The S&P 500 recently hit the 7,000 mark but failed to close above it, indicating market fragility at high levels, which could affect investor confidence and lead to short-term volatility.
- Sector Leadership Shift: In 2026, sectors like energy, materials, and staples have shown impressive gains of 22.5%, 16.9%, and 13.3%, respectively, but these sectors typically lead near market tops, suggesting current leadership may lack sustainability.
- Healthcare Sector Recovery: The healthcare ETF (XLV) is up only 1.9% year-to-date, yet major components like Merck, Johnson & Johnson, and Amgen are trading near 52-week highs, indicating potential upside and positioning it as a likely next market leader.
- Investment Strategy Adjustment: Investors should focus on the healthcare sector's technical breakout, particularly the crucial $160 level; if cleared, upside targets could reach the mid-180s, signaling increasing investment opportunities in the healthcare sector within the current market environment.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Slow Growth in Medicare Advantage Enrollment Amid Insurer Pullback
- Enrollment Growth: As of February 1, approximately 35.5 million Americans were enrolled in Medicare Advantage (MA), reflecting nearly a 3% increase from last year, indicating the program's ongoing appeal among older adults and individuals with disabilities.
- Slowing Growth Rate: Despite the increase in enrollment, the annual growth rate for 2025 is only 1%, a significant decline from the historical average of 7%-10% between 2017 and 2024, highlighting market fatigue and intensified competition.
- Insurer Pullback: Nearly all health insurers, including UnitedHealth (UNH) and CVS Health (CVS), have been scaling back their market presence, contributing to the overall slowdown, with only Humana (HUM) increasing its enrollment numbers.
- Market Competition Landscape: UnitedHealth (UNH) remains the largest operator in the MA market, followed by Humana (HUM), while other players like CVS Health's Aetna unit, Clover Health (CLOV), and Alignment Healthcare (ALHC) also hold significant positions in the market.
See More
Mubadala Investment Co PJSC Reduces ARM Holdings PLC Share Stake by 8.3% to 1.4 Million Sponsored ADS, According to SEC Filing
- Investment Stake Reduction: Mubadala Investment Company has cut its share stake in Arm Holdings by 8.3%, reducing its ownership to 1.4 million shares.
- Sponsored Ads Impact: The reduction in stake is highlighted in a recent SEC filing, indicating potential implications for sponsored ads and investment strategies.
See More
Mubadala Investment Co PJSC Reduces Stake in Adobe Inc by 49.0% to 11,570 Shares, According to SEC Filing
- Investment Stake: Mubadala has cut its share stake in Adobe by 49.0%, reducing its holdings to 11,570 shares.
- Regulatory Filing: The reduction in shares was disclosed in a recent SEC filing.
See More
CVS Health Launches $5 Million Pharmacy Scholarship Program
- Scholarship Program Launch: CVS Health has announced a new $5 million scholarship program aimed at supporting aspiring pharmacists in Louisiana, facilitating their pursuit of a Doctor of Pharmacy degree at Xavier University and the University of Louisiana at Monroe, thereby reducing financial barriers and enhancing access to care.
- Commitment to Health Equity: This initiative is part of CVS Health's broader commitment to advancing health equity and expanding access to care by investing in the next generation of healthcare professionals, particularly those from diverse backgrounds who wish to serve in areas with critical healthcare needs.
- Community Impact: Louisiana Governor Jeff Landry emphasized that investing in young people is crucial for the state's future, and CVS Health's initiative will strengthen the local healthcare workforce while promoting overall community health by providing opportunities for education and career development.
- Educational Partnerships: Xavier University and the University of Louisiana at Monroe were selected for their shared commitment to academic excellence and community impact, and CVS Health's scholarship program will create clear pathways for talented individuals to remain in the state and contribute to local healthcare services.
See More
Market Rotation and Healthcare Sector Outlook
- Market Milestones: The S&P 500 recently hit the 7,000 mark but failed to close above it, indicating market fragility at high levels, which could affect investor confidence and lead to short-term volatility.
- Sector Leadership Shift: In 2026, sectors like energy, materials, and staples have shown impressive gains of 22.5%, 16.9%, and 13.3%, respectively, but these sectors typically lead near market tops, suggesting current leadership may lack sustainability.
- Healthcare Sector Recovery: The healthcare ETF (XLV) is up only 1.9% year-to-date, yet major components like Merck, Johnson & Johnson, and Amgen are trading near 52-week highs, indicating potential upside and positioning it as a likely next market leader.
- Investment Strategy Adjustment: Investors should focus on the healthcare sector's technical breakout, particularly the crucial $160 level; if cleared, upside targets could reach the mid-180s, signaling increasing investment opportunities in the healthcare sector within the current market environment.
See More
FDA Pushes for Prescription Drugs to Become Over-the-Counter
- Policy Advocacy: FDA Commissioner Marty Makary stated in Washington that the agency plans to push for more prescription drugs to become over-the-counter (OTC) this year, aiming to improve drug accessibility and reduce healthcare costs, which could allow patients to obtain basic safe medications without a doctor's visit.
- Regulatory Streamlining: Legislation passed by Congress in November simplifies the regulatory process for transitioning prescription drugs to OTC status, including full, conditional, and partial switch pathways, which is expected to accelerate drug availability and enhance patient convenience in medication access.
- Increased Transparency: Makary emphasized that OTC sales would bypass insurers and pharmacy benefit managers, potentially lowering drug prices and increasing transparency, with cash prices for OTC medications possibly being lower than patients' copays for prescription drugs, thereby alleviating financial burdens on patients.
- Industry Pushback: The pharmaceutical industry has raised concerns about this policy, arguing that OTC drugs may not be covered by insurance, leading to higher costs for patients, and that the FDA lacks authority over drug pricing, necessitating thorough consultations with manufacturers before any transitions.
See More
Slow Growth in Medicare Advantage Enrollment Amid Insurer Pullback
- Enrollment Growth: As of February 1, approximately 35.5 million Americans were enrolled in Medicare Advantage (MA), reflecting nearly a 3% increase from last year, indicating the program's ongoing appeal among older adults and individuals with disabilities.
- Slowing Growth Rate: Despite the increase in enrollment, the annual growth rate for 2025 is only 1%, a significant decline from the historical average of 7%-10% between 2017 and 2024, highlighting market fatigue and intensified competition.
- Insurer Pullback: Nearly all health insurers, including UnitedHealth (UNH) and CVS Health (CVS), have been scaling back their market presence, contributing to the overall slowdown, with only Humana (HUM) increasing its enrollment numbers.
- Market Competition Landscape: UnitedHealth (UNH) remains the largest operator in the MA market, followed by Humana (HUM), while other players like CVS Health's Aetna unit, Clover Health (CLOV), and Alignment Healthcare (ALHC) also hold significant positions in the market.
See More
Mubadala Investment Co PJSC Reduces ARM Holdings PLC Share Stake by 8.3% to 1.4 Million Sponsored ADS, According to SEC Filing
- Investment Stake Reduction: Mubadala Investment Company has cut its share stake in Arm Holdings by 8.3%, reducing its ownership to 1.4 million shares.
- Sponsored Ads Impact: The reduction in stake is highlighted in a recent SEC filing, indicating potential implications for sponsored ads and investment strategies.
See More
Mubadala Investment Co PJSC Reduces Stake in Adobe Inc by 49.0% to 11,570 Shares, According to SEC Filing
- Investment Stake: Mubadala has cut its share stake in Adobe by 49.0%, reducing its holdings to 11,570 shares.
- Regulatory Filing: The reduction in shares was disclosed in a recent SEC filing.
See More
